Skip to main content
Kringle Pharma,Inc. logo

Kringle Pharma,Inc. — Investor Relations & Filings

Ticker · 4884 ISIN · JP3270790003 T Manufacturing
Open in API
Filings indexed 53 across all filing types
Latest filing 2024-12-23 Governance Information
Country JP Japan
Listing T 4884

About Kringle Pharma,Inc.

https://www.kringle-pharma.com/en/

Kringle Pharma, Inc. is a late clinical-stage biopharmaceutical company focused on the research and development of regenerative medicines for intractable and rare diseases. The company's core technology is based on recombinant human Hepatocyte Growth Factor (HGF), an endogenous protein with tissue-protective, regenerative, and repairing functions. Kringle Pharma has established a platform to manufacture pharmaceutical-grade HGF protein and is conducting clinical trials for several indications. Key development programs target conditions including acute spinal cord injury, vocal fold scarring, and Amyotrophic Lateral Sclerosis (ALS).

Recent filings

Filing Released Lang Actions
内部統制報告書－第23期(2023/10/01－2024/09/30)
Governance Information Classification · 100% confidence The document explicitly states its title and purpose multiple times, including in the header: "【提出書類】 内部統制報告書" (Filing Document: Internal Control Report) and the text body: "内部統制報告書" (Internal Control Report). It references the legal basis under the Financial Instruments and Exchange Act (金融商品取引法第24条の４の４第１項) and details the scope, criteria, and conclusion of the assessment of internal controls over financial reporting as of the fiscal year-end (2024年９月30日). This structure and content perfectly match the definition of an Audit Report / Information (AR), which covers internal or regulatory stress tests and applied accounting principles, although this specific report focuses on internal controls over financial reporting, which is closely related to audit assurance and often filed alongside annual reports but distinct from the full 10-K. Given the specific focus on 'Internal Control Report' (内部統制報告書), which is a required disclosure related to financial reporting assurance, the closest fit among the provided codes is 'AR' (Audit Report / Information), as it covers reports on internal controls and applied accounting principles, distinct from the comprehensive 10-K or a simple earnings release (ER).
2024-12-23 Japanese
臨時報告書
AGM Information Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and explicitly states in Section 1 that it is being filed pursuant to Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act, following a resolution passed at an Extraordinary General Meeting of Shareholders held on August 23, 2024. The content details the resolution regarding the reduction of capital and capital reserves, and the appropriation of surplus, along with voting results. This structure—a formal filing announcing the results of a shareholder meeting resolution—most closely aligns with the purpose of reporting voting outcomes, which falls under Declaration of Voting Results & Voting Rights Announcements (DVA). While it relates to a shareholder meeting, it is specifically reporting the *results* of the vote, not the proxy materials (PSI) or the AGM presentation itself (AGM-R). Given the Japanese regulatory context, this type of filing reporting specific resolutions and voting outcomes is best categorized as DVA.
2024-08-26 Japanese
四半期報告書－第23期第2四半期(2024/01/01－2024/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Kringle Pharma, Inc., covering the period from January 1, 2024, to March 31, 2024. It contains detailed financial statements, management analysis of financial conditions, and business results, which aligns with the definition of an Interim/Quarterly Report (IR). Q2 2024
2024-05-13 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document text contains the header "第２四半期報告書" (Second Quarter Report) and specifies the period covered: "第23期第２四半期（自 2024年１月１日 至 2024年３月31日）". It also includes confirmation statements regarding the appropriateness of the filing content, referencing the Financial Instruments and Exchange Act ("金融商品取引法"). This structure strongly indicates a comprehensive financial report for an interim period shorter than a year. This aligns perfectly with the definition of an Interim / Quarterly Report (Code: IR). The document length is short (617 chars), but the content is the substance of the report confirmation, not just an announcement of publication, making IR more appropriate than RPA or RNS.
2024-05-13 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is titled "第１四半期報告書" (First Quarter Report) and explicitly states the reporting period: "第23期第１四半期（自 2023年10月１日 至 2023年12月31日）". It includes confirmation statements regarding the appropriateness of the quarterly report's contents, filed with the Kinki Local Finance Bureau. This structure and content strongly indicate a comprehensive financial report covering a period shorter than a year, which corresponds to the definition of an Interim / Quarterly Report (IR). The document length is very short (618 chars), but the content is the substance of the report confirmation itself, not just an announcement of publication, making IR the most appropriate classification over RPA/RNS.
2024-02-09 Japanese
四半期報告書－第23期第1四半期(2023/10/01－2023/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Kringle Pharma, Inc., covering the first quarter of the 23rd fiscal period (October 1, 2023, to December 31, 2023). It contains detailed financial statements (balance sheet, income statement) and management analysis, which aligns with the definition of an Interim/Quarterly Report (IR). It is not an announcement of a report, but the report itself. Q1 2023
2024-02-09 Japanese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.